+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 165 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying the usefulness of 3D-printed tooth replicas combined with autotransplantation of teeth in children and young adults who need tooth transplantation. This study is designed to compare the 3D generated tooth replicas with the conventional methods to see if the new technology improves the surgical process and success of tooth transplantation. The study is led by Turku University Hospital and includes participants aged 9 to 23 years. Participants will undergo tooth autotransplantation surgery using either a 3D-printed tooth replica or a conventional procedure. Researchers will evaluate factors such as the duration of surgery and the degree of manipulation needed during the transplant procedure. They will also assess how well the transplanted tooth erupts and develops its roots over time. Participants will be followed for one year after surgery. During this time, clinical and radiological examinations will be performed to determine the health of the transplanted teeth. The main outcomes measured include the number of patients with healthy transplanted teeth at one year. This monitoring will help researchers understand the effectiveness of using 3D replicas in tooth autotransplantation.

Age: 9Years - 23YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Prostate cancer is the most common cancer among men in Finland, with up to 20% of cases being metastatic at diagnosis and causing significant mortality. Accurate initial staging is crucial for deciding the best treatment approach. Current recommended imaging methods like bone scintigraphy and whole body CT have low sensitivity for detecting metastasis. This trial evaluates a new imaging agent, 99mTc-MIP-1404, used in SPECTCT scans, which binds to the PSMA molecule found on prostate cancer cells and may improve detection accuracy. Participants are randomly assigned to one of two groups for comparison. The control group undergoes traditional imaging with bone scintigraphy and whole body CT. The experimental group receives these standard scans plus additional imaging using 99mTc-MIP-1404 SPECTCT and 18F-PSMA-1007 PETCT. The 99mTc-MIP-1404 is administered as a single intravenous dose. The study aims to determine if this new imaging method is superior in identifying local lymph node metastases and overall metastasis in men with high-risk prostate cancer. During the study, researchers assess the presence of metastases using various imaging techniques and compare their diagnostic accuracy. They evaluate true and false positive and negative rates, inter-rater agreement, and how imaging results influence treatment decisions. Participants are monitored at baseline, and their involvement includes multiple imaging sessions. The trial helps clarify if 99mTc-MIP-1404 SPECTCT can enhance prostate cancer staging and guide better treatment planning.

Age: 18Years +MALEPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are conducting an open-label, multi-site, multi-cohort phase 12 trial to evaluate ODM-212 combined with other anti-cancer therapies in adults with advanced solid tumors such as mesothelioma, pancreatic cancer, and advanced non-small cell lung cancer NSCLC. The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and effectiveness of these combinations. The trial is divided into two parts dose escalation and dose expansionoptimization. Participants receive ODM-212 tablets alongside specified anti-cancer therapies depending on their cancer type. These include ipilimumab and nivolumab for mesothelioma, gemcitabine with nab-paclitaxel for pancreatic cancer, and sotorasib for NSCLC with a KRAS G12C mutation. Each drug has specific dosing schedules, such as intravenous infusions every 3 to 6 weeks or daily oral dosing in 21-day cycles. Participants will be monitored throughout the study for dose-limiting toxicities and adverse events over an average of 2 years. They will record daily adherence to oral medications and undergo evaluations including tumor biopsies and response assessments. The study involves regular visits for treatment administration and safety monitoring, with eligibility requiring good performance status and the ability to take oral medication.

Age: 18Years +All GendersPhase 1Phase 2
23 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
S

Actively Recruiting

Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.

Age: 18Years +FEMALEPhase 3
167 locations
E

Actively Recruiting

Researchers are evaluating a financial social work program called FinSoc designed to support families facing complex financial difficulties, especially those with children under 18. The study aims to improve financial skills, reduce financial anxiety, and enhance overall well-being. This randomized controlled trial compares the FinSoc intervention with usual social work services to assess its impact on families financial literacy and related outcomes. The FinSoc program consists of five sessions delivered one-on-one by trained social workers. These sessions focus on budgeting, decision-making, emotional and relational aspects of money, and building long-term financial capability. Families in the experimental group receive this structured program, while the control group continues with regular social work services and receives a materials package after the final measurement. Participants will be involved in assessments at three times before the intervention, shortly after it ends, and three months later. These include questionnaires measuring financial literacy, financial anxiety, economic self-efficacy, and health-related quality of life. Additionally, some families and social workers will be interviewed to gather feedback on their experiences with the program. Social workers will also report on how closely they followed the intervention plan after each session. The study seeks to inform social work practices and improve families everyday financial well-being.

All AgesAll GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are investigating BAY 3547926, a new drug designed to treat advanced hepatocellular carcinoma HCC, a type of liver cancer that shows a specific protein called Glypican 3 GPC3. This first-in-human study aims to evaluate the safety, how well the drug works, and the best dose for patients with advanced HCC. The drug works by delivering a radioactive agent to cancer cells to damage and kill them with minimal harm to nearby healthy tissues. Participants will join one of four parts of the study. In Part 1, different doses of BAY 3547926 alone will be tested to find the safest and most effective dose. Then, in Part 2, a larger group will receive the chosen dose alone, while Parts 3 and 4 will explore BAY 3547926 combined with other treatments. The study uses an open-label design without randomization, and the drug is given as an antibody conjugate labeled with actinium-225. Throughout the study, participants will have health check-ups, imaging scans, and blood and urine sample collections. They will also be asked about their health status and symptoms. Researchers will monitor side effects, drug absorption and distribution, and tumor response using imaging criteria. The study tracks outcomes for up to 60 months after the first drug administration to evaluate safety, anti-tumor activity, and pharmacokinetics.

Age: 18Years +All GendersPhase 1
36 locations
P

Actively Recruiting

Researchers are evaluating ODM-212, a drug being studied in a first-in-human, multi-site, open-label Phase 12 clinical trial involving adults with selected advanced solid tumors that cannot be treated with curative intent. The study aims to assess the safety and side effects of ODM-212 in patients who have cancers such as mesothelioma, lung carcinoma, colorectal cancer, and others with specific genetic alterations. This research is sponsored by Orion Corporation, Orion Pharma. Participants receive ODM-212 tablets at doses of 5mg andor 40mg. The study has two parts an initial dose escalation phase to find a safe dose, followed by a dose expansion phase that includes patients with solid tumors harboring specific genetic pathway alterations. Treatments are given orally, and dosing details are adjusted based on patient response and safety observations. During the study, participants will be monitored from the first dose until one year after the last study visit to track treatment-emergent adverse events and their severity. Regular assessments include physical exams, laboratory tests, and performance status evaluations. Participants must comply with the protocol and provide informed consent. The total study duration varies based on treatment and follow-up schedules.

Age: 18Years +All GendersPhase 1Phase 2
20 locations
O

Actively Recruiting

Researchers are studying the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006, an RNA editing oligonucleotide, in people with alpha-1 antitrypsin deficiency AATD who have the Pi*ZZ genetic variant. This open-label study includes single ascending dose and multiple ascending dose periods to better understand how the drug behaves in the body and its potential effects on this condition. Participants will receive different doses of WVE-006 in two periods first, a single ascending dose phase and then a multiple ascending dose phase. The study will monitor how the body absorbs and processes the drug over up to 36 weeks. The research aims to evaluate changes in serum M-AAT protein levels and measure drug concentrations in plasma during these treatment periods. Throughout the study, participants will undergo medical evaluations to assess safety and drug effects, including monitoring adverse events and blood tests to measure protein levels and drug amounts in the blood. The study will last up to 36 weeks, with ongoing assessments of safety and drug activity. Participants will be followed closely to gather information about how the treatment is tolerated and processed by the body.

Age: 18Years - 70YearsAll GendersPhase 1Phase 2
9 locations
D

Actively Recruiting

Healthy Volunteer

Researchers are conducting a prospective diagnostic trial to study Al18FF-NOTA-folate PET imaging in adults with suspected cardiac sarcoidosis or infective endocarditis, along with healthy volunteers. The purpose is to assess imaging features, diagnostic accuracy, radiation dose, and safety of this imaging method. The study is non-interventional regarding clinical care, with treatment decisions made independently from study participation. Participants will undergo PET imaging using the Al18FF-NOTA-folate tracer, covering head to mid-thigh regions to assess uptake in heart and other tissues. In patients with suspected cardiac sarcoidosis, resting myocardial perfusion imaging with 15Owater PET and echocardiography will also be performed. Those with suspected cardiac sarcoidosis will have a second PET scan after starting immunosuppressive therapy. The imaging visits include collection of blood samples, ECG, and vital signs. During the study, researchers will measure quantitative tracer uptake in the heart muscle and valves, compare infected versus non-infected valves, and evaluate changes after treatment. Safety will be monitored through adverse event assessment and laboratory tests, with follow-up ranging from hours for healthy volunteers to up to two years for patient groups. The trial aims to complete by the end of 2030.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 165

1